BIIB074 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Lumbosacral Radiculopathy

Conditions

Lumbosacral Radiculopathy

Trial Timeline

Oct 31, 2016 → Aug 6, 2018

NCT ID

NCT02935608

About BIIB074 + Placebo

BIIB074 + Placebo is a phase 2 stage product being developed by Biogen for Lumbosacral Radiculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02935608. Target conditions include Lumbosacral Radiculopathy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03070132	Phase 3	Withdrawn	Apr 19, 2023	Aug 21, 2026	Trigeminal Neuralgia
NCT03637387	Phase 3	Withdrawn	Mar 1, 2023	Sep 29, 2026	Trigeminal Neuralgia
NCT03339336	Phase 2	Terminated	May 31, 2018	Apr 12, 2021	Small Fiber Neuropathy
NCT02935608	Phase 2	Completed	Oct 31, 2016	Aug 6, 2018	Lumbosacral Radiculopathy
NCT02917187	Phase 2	Completed	Sep 9, 2016	Jan 5, 2017	Primary Inherited Erythromelalgia
NCT02831517	Phase 1	Completed	Aug 1, 2016	Feb 1, 2017	Healthy

Competing Products

5 competing products in Lumbosacral Radiculopathy

See all competitors

Product	Company	Stage	Hype Score
VX-548 + Placebo	Vertex Pharmaceuticals	Phase 2	51
CNV1014802 + Placebo	Biogen	Phase 2	49
BIIB074	Biogen	Phase 2	49
SP-102 + Placebo	Scilex Holding	Phase 3	69
SP-102	Scilex Holding	Phase 2	44

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved

Dimethyl fumarateApproved

[18F]Florbetapir PET imagingApproved

dimethyl fumarateApproved

ibritumomab tiuxetan (Zevalin®)Approved